ArticleNucleic acids research2026
NPASS database update 2026: comprehensive quantitative composition, bioactivity, and ADME-Tox data of natural products for biomedical research.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Machine learning-driven identification of PIM2 kinase inhibitors through QSAR modeling and molecular dynamics simulations.Journal, genetic engineering & biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Bioactive natural products (NPs) are valuable sources for biomedical and various applications. Comprehensive information on their species sources and quantitative properties (including compositions, bioactivities, and toxicities) is of great utility to the research community. Here, we introduced NPASS 3.0 with major updates to significantly expand the previous version and add new data derived from emerging technologies. Firstly, we manually curated new records from 1822 publications to provide: (i) an additional 87 507 quantitative composition records for 4873 NPs in 1030 species and (ii) 878 NPs produced by 341 symbiont organisms and 164 elicitor-responsive organisms, together with an additional 109 engineered organisms and 43 co-culture organisms. Secondly, 34 975 new quantitative toxicity records for 3662 NPs and 9713 quantitative ADME records for 744 NPs. Thirdly, this update substantially increased the records of NPASS, with 9.37%-206.30% data expansion over NPASS 2.0. Currently, NPASS includes 204 023 NPs, 48 940 organisms, 8764 targets, 1 048 756 experimental activity records, 34 975 toxicity records, 9713 quantitative ADME records, 208 415 NP composition records, and 1 117 269 organism-NP pairs. Furthermore, bioactivities were grouped into three classes for better serving pharmaceutical research. We also updated the NPASS web interface, which includes an enhanced search option and a submission page for crowdsourcing curation. NPASS 3.0 is accessible at https://bidd.group/NPASS/index.php.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.